凱淳股份(301001.SZ):董事親屬短線交易
格隆匯6月3日丨凱淳股份(301001.SZ)公佈,公司近日收到董事譚崢嶸《關於短線交易的情況説明及致歉聲明》,獲悉其配偶陳玲分別於2021年6月1日及2021年6月2日買賣公司股票,其買賣行為構成短線交易,現將有關情況公吿如下:

公司知悉此次事件發生後,高度重視,及時核查相關情況,譚崢嶸及其配偶陳玲亦積極配合、主動糾正。
陳玲的上述交易行為違反了上述規定,構成短線交易。此次短線交易產生的收益為:交易數量1000×(賣出價57.1000-買入價53.0000)=4100元,在扣除交易税費後累計盈利人民幣3968.03元。根據《證券法》的規定,陳玲短線交易所獲盈利3968.03元將上交公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.